NatureCell (CEO Ju-Sun Kim and Dae-joong Byun) announced on July 17th the presentation of their research findings on the clinical efficacy of their advanced degenerative arthritis stem cell treatment, "Jointstem," at the 30th Annual Meeting of the Japan Society of Gene and Cell Therapy held in Yokohama from July 16th to 18th. The presentation was conducted by Professor Jang-Ik Lee's team from the College of Pharmacy at Seoul National University

Professor Lee detailed the results of Jointstem's Phase 1, 2, and 3 clinical trials, along with a three-year follow-up study. In the Phase 3 trial, Jointstem showed statistically significant improvements in the primary efficacy endpoints, VAS and WOMAC scores, compared to the control group. Furthermore, the three-year follow-up study of Phase 3 patients revealed fewer cases of joint replacement surgery in the Jointstem group compared to the control group.

In the control group, eight patients underwent joint replacement surgery, whereas only two patients in the Jointstem group required such surgery, demonstrating the sustained efficacy of Jointstem over three years. Professor Lee stated, "The data clearly confirms the efficacy of Jointstem."

Professor Jang-Ik Lee added, "The clinical results of Jointstem are expected to prevent surgical treatments such as knee replacement surgery for osteoarthritis patients and address the unmet needs of patients who cannot undergo surgery."